RGD Reference Report - Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease.

Authors: Kamgar, M  Nobakhthaghighi, N  Shamshirsaz, AA  Estacio, RO  McFann, KK  Schrier, RW 
Citation: Kamgar M, etal., Kidney Int. 2006 May;69(10):1899-903.
RGD ID: 2311671
Pubmed: PMID:16598198   (View Abstract at PubMed)
DOI: DOI:10.1038/sj.ki.5000355   (Journal Full-text)

Progression of renal disease and cardiovascular complications in type II diabetes mellitus have been shown to correlate with control of blood glucose, lipids, blood pressure, and smoking. These factors, however, do not appear to totally explain these diabetic complications. Renal disease and cardiovascular complications in type II diabetes are associated with vascular abnormalities and fibrosis, both of which may occur with impaired fibrinolysis. A cross-sectional study was therefore performed in 107 type II diabetic patients recruited from the Denver Metropolitan Area to examine the effect of impaired fibrinolysis, as assessed by the ratio of plasminogen activator inhibitor (PAI-1) to tissue-type plasminogen activator (t-PA). With urinary albumin excretion (UAE) as a risk factor for both renal disease progression and cardiovascular complications, the patients were analyzed with respect to UAE less than and greater than 1 gm/day. The age, blood glucose, hemoglobin A1C, duration of diabetes, lipids, body mass index, and smoking were no different between the groups. As expected, the group with greater UAE had worse renal function, the serum creatinine (1.98 +/- 0.24 vs 1.21 +/- 0.05 mg/dl, P < 0.001) and creatinine clearance (55.5 +/- 6.0 vs 76.8 +/- 2.7 ml/min, P < 0.001) were significantly different. The type II diabetic patients with greater UAE exhibited significantly higher PAI-1/t-PA (2.43 +/- 0.26 vs 1.85 +/- 0.07, P < 0.03). The past history of cardiac complications was also higher (87.5 vs 72.3%, P < 0.07) in the diabetic patients with more impaired fibrinolysis and greater UAE. Thus a prospective, randomized clinical trial in type II diabetes with PAI-1 inhibitors is needed.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Diabetic Nephropathies  IEP 2311671associated with Diabetes Mellitus and Non-Insulin-DependentRGD 
Diabetic Nephropathies  ISOPLAT (Homo sapiens)2311671; 2311671associated with Diabetes Mellitus and Non-Insulin-DependentRGD 

Objects Annotated

Genes (Rattus norvegicus)
Plat  (plasminogen activator, tissue type)

Genes (Mus musculus)
Plat  (plasminogen activator, tissue)

Genes (Homo sapiens)
PLAT  (plasminogen activator, tissue type)


Additional Information